Showing 3741-3750 of 5773 results for "".
- Novartis Acquires Kedalion Therapeutics and its Ocular Delivery Platformhttps://modernod.com/news/novartis-acquires-kedalion-therapeutics-and-its-ocular-delivery-platform/2480952/Novartis announced that it has acquired Kedalion Therapeutics and its AcuStream technology, a device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye.1,2 Terms of the deal were
- RetinalGeniX Technologies Acquires DNA/GPS Inc.https://modernod.com/news/retinalgenix-technologies-acquires-dnagps-inc/2480949/RetinalGeniX Technologies announced the acquisition of DNA/GPS. Terms of the deal were not disclosed. The acquisition gives RetinalGeniX the rights to the platform technology designed by Larry Perich, MD, which is designed to al
- Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimurahttps://modernod.com/news/iveric-bio-and-delsitech-enter-exclusive-agreement-for-development-of-sustained-release-zimura/2480948/Iveric bio and DelSiTech announced an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. Under the terms of the l
- Aetna Drops Prior Authorization for Most Cataract Surgerieshttps://modernod.com/news/aetna-drops-prior-authorization-requirement-for-cataract-surgery/2480944/Aetna announced this week that it will no longer require preauthorization for cataract&nbs
- Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMDhttps://modernod.com/news/adverum-biotechnologies-granted-priority-medicines-prime-designation-by-european-medicines-agency-for-advm-022-in-wet-amd/2480943/Adverum Biotechnologies announced that the European Medicines Agency (EMA) has granted ADVM-022 Priority Medicines (PRIME) designation for the treatment of wet age-related macular degeneration (AMD). Adverum’s lead gene therapy candidate, ADVM-022, is a one-time, intr
- Ocuphire Granted New US Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabeticshttps://modernod.com/news/ocuphire-granted-new-us-patent-for-late-stage-oral-drug-candidate-apx3330-for-use-in-diabetics/2480941/Ocuphire Pharma announced that the United States Patent and Trademark Office (USPTO) has issued a new patent extending expiry and broadening coverage of the company’s late-stage oral product candidate, APX3330, for diabetic eye disease. In addition, a new publication supporting the nov
- EssilorLuxottica Chairman Leonardo Del Vecchio Passes Away at Age 87https://modernod.com/news/essilorluxottica-chairman-leonardo-del-vecchio-passes-away-at-age-87/2480931/Italian fashion icon Leonardo Del Vecchio, chairman of EssilorLuxottica, passed away at the age of 87, the company announced Monday. "The company expresses its deepest condolences to the family and to the global employee community for this enormous loss. The Board will m
- LumiThera Presents New Data from LIGHTSITE III Trial Showing Improvement in Vision in Intermediate Dry AMDhttps://modernod.com/news/lumithera-presents-new-data-from-lightsite-iii-trial-showing-improvement-in-vision-in-intermediate-dry-amd/2480930/LumiThera announced detailed findings in its LIGHTSITE III, multicenter clinical trial in non-neovascular age-related macular degeneration (AMD) subjects treated with photobiomodulation (PBM) using the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked,
- Opus Genetics Appoints Ben Yerxa, PhD, as Permanent Chief Executive Officerhttps://modernod.com/news/opus-genetics-appoints-ben-yerxa-phd-as-permanent-chief-executive-officer/2480923/Opus Genetics announced the appointment of Ben Yerxa, PhD, as Chief Executive Officer. Dr. Yerxa previously served as acting CEO of Opus, in addition to former roles as CEO of the Foundation Fighting Blindness and the Retinal Degeneration (RD) Fund, the venture arm of th
- Ace Vision Group Appoints Elizabeth Yeu, MD, as Chief Strategic Advisorhttps://modernod.com/news/ace-vision-group-appoints-elizabeth-yeu-md-as-chief-strategic-advisor/2480922/Ace Vision Group announced that Elizabeth Yeu, MD, partner at Virginia Eye Consultants, has been appointed to the role of chief strategic advisor. In her new position, Dr. Yeu will manage AVG's clinical advancement strategy. As a surgeon, researcher, and educator, Dr.